We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Global POC Diagnostics/Testing Market to Reach USD 22.8 Billion by 2025

By LabMedica International staff writers
Posted on 03 May 2019
Print article
The global point of care (POC) diagnostics/testing market size is expected to grow at a CAGR of 3.3% over the forecast period 2019-2025 to reach USD 22.8 billion by 2025, driven by the ability of POC tests to render rapid and accurate results at bedside settings and in remote areas. The market growth is being further aided by the adoption of automated laboratory systems and highly integrated solutions that facilitate the diagnostic workflow.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Increasing R&D activities by the key players for introducing novel POC tests and devices for the rapid detection and monitoring of diseases is expected to further boost the growth of the POC testing market. Additionally, the lack of skilled professionals or medical personnel with limited training, especially in diagnostics, who can also easily use these devices is also fueling the growth of the POC diagnostics/testing market. Moreover, the high prevalence of chronic disorders and cancer is resulting in a large customer base adopting cost-effective and immediate diagnostic tests, thereby propelling the growth of the POC diagnostics/testing market. This is further supplemented by a number of favorable initiatives to promote the employment of POC tests in diagnosis and screening procedures.

Based on product, the glucose testing segment dominated the POC diagnostics/testing market in 2018 in terms of revenue due to the high prevalence of diabetes and introduction of a wide variety of glucose meters by companies. The Hb1Ac testing segment is also expected to show a similar trend due to stiff competition for delivering low-cost Hb1Ac tests among the key players in the market. The detection and analysis of circulating tumor cells during cancer progression is expected to help the cancer marker segment achieve the fastest penetration rate over the coming years.

Based on end-user, the clinics segment dominated the POC diagnostics/testing market with the largest revenue share in 2018, due to the employment of a wide range of POC tests. On the other hand, increasing awareness about decentralized tests among patients is driving a lucrative growth in home-based POC testing.

Geographically, the US is likely to dominate the North American POC diagnostics/testing market due to the presence of key players undertaking significant research activities in the country. Also, the POC diagnostics/testing market in Asia Pacific holds significant potential for growth due to continuous developments in the region’s healthcare sector for introducing novel and accurate diagnostic tests.

Related Links:
Research and Markets

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.